Chattem Considering OTC Cough/Cold, GI Tract Purchases, Exec Says
This article was originally published in The Tan Sheet
Executive Summary
Chattem is eyeing the OTC cough/cold and gastrointestinal tract categories as possible areas for expansion through acquisition, President & Chief Operating Officer Alec Taylor said at a BB&T Capital Markets Equity Research Conference in Leesburg, Va. May 21
You may also be interested in...
J&J Adds Cortaid, Insight Gets Bonine In Pfizer/Pharmacia Pre-Merger Sell Off
Johnson & Johnson will add Pharmacia's Cortaid OTC anti-itch and rash line to its skin remedies business in one of several divestitures planned to resolve Federal Trade Commission concerns regarding potential monopolies resulting from the merger of Pharmacia and Pfizer
Chattem Selsun Blue Purchase Provides Entry Into Five New Foreign Markets
Line extensions and a major marketing push are among the growth tactics Chattem expects to pursue when it brings Selsun Blue into its consumer health portfolio. Chattem has agreed to purchase the anti-dandruff line from Abbott Labs subsidiary Ross Products
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC